Cargando…
Osimertinib in combination with bevacizumab in EGFR-Mutated NSCLC with leptomeningeal metastases
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7815344/ https://www.ncbi.nlm.nih.gov/pubmed/33489813 http://dx.doi.org/10.21037/tlcr-20-984 |
| _version_ | 1783638209481146368 |
|---|---|
| author | Jiang, Tao Xu, Xiaobo Chen, Xiaojuan Ding, Ning Hu, Qin Zhou, Caicun Hu, Jie |
| author_facet | Jiang, Tao Xu, Xiaobo Chen, Xiaojuan Ding, Ning Hu, Qin Zhou, Caicun Hu, Jie |
| author_sort | Jiang, Tao |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7815344 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | AME Publishing Company |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-78153442021-01-22 Osimertinib in combination with bevacizumab in EGFR-Mutated NSCLC with leptomeningeal metastases Jiang, Tao Xu, Xiaobo Chen, Xiaojuan Ding, Ning Hu, Qin Zhou, Caicun Hu, Jie Transl Lung Cancer Res Letter to the Editor AME Publishing Company 2020-12 /pmc/articles/PMC7815344/ /pubmed/33489813 http://dx.doi.org/10.21037/tlcr-20-984 Text en 2020 Translational Lung Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
| spellingShingle | Letter to the Editor Jiang, Tao Xu, Xiaobo Chen, Xiaojuan Ding, Ning Hu, Qin Zhou, Caicun Hu, Jie Osimertinib in combination with bevacizumab in EGFR-Mutated NSCLC with leptomeningeal metastases |
| title | Osimertinib in combination with bevacizumab in EGFR-Mutated NSCLC with leptomeningeal metastases |
| title_full | Osimertinib in combination with bevacizumab in EGFR-Mutated NSCLC with leptomeningeal metastases |
| title_fullStr | Osimertinib in combination with bevacizumab in EGFR-Mutated NSCLC with leptomeningeal metastases |
| title_full_unstemmed | Osimertinib in combination with bevacizumab in EGFR-Mutated NSCLC with leptomeningeal metastases |
| title_short | Osimertinib in combination with bevacizumab in EGFR-Mutated NSCLC with leptomeningeal metastases |
| title_sort | osimertinib in combination with bevacizumab in egfr-mutated nsclc with leptomeningeal metastases |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7815344/ https://www.ncbi.nlm.nih.gov/pubmed/33489813 http://dx.doi.org/10.21037/tlcr-20-984 |
| work_keys_str_mv | AT jiangtao osimertinibincombinationwithbevacizumabinegfrmutatednsclcwithleptomeningealmetastases AT xuxiaobo osimertinibincombinationwithbevacizumabinegfrmutatednsclcwithleptomeningealmetastases AT chenxiaojuan osimertinibincombinationwithbevacizumabinegfrmutatednsclcwithleptomeningealmetastases AT dingning osimertinibincombinationwithbevacizumabinegfrmutatednsclcwithleptomeningealmetastases AT huqin osimertinibincombinationwithbevacizumabinegfrmutatednsclcwithleptomeningealmetastases AT zhoucaicun osimertinibincombinationwithbevacizumabinegfrmutatednsclcwithleptomeningealmetastases AT hujie osimertinibincombinationwithbevacizumabinegfrmutatednsclcwithleptomeningealmetastases |